Accelerated Preclinical Development of Cell Therapies

Use IsoPlexis' IsoCode chip for single-cell profiling of humanized mice in preclinical translational development of CAR-T and TCR-T cellular therapies.

IsoCode Data

Figure 1: Polyfunctionality and Polyfunctional Strength are considerably increased in samples treated with ACT+NKTR-214 vs ACT+IL-2.

Figure 2: Heatmap reveals that NKTR-214 elicits more polyfunctional cell subsets in the adoptively transferred TCR-T cells in spleen and tumor compared to IL-2.


Parisi G, Saco J, Salazar F, Krystofinski P, Tsoi J, Zhang R, Puig Saus C, Zhou J, Hu-Lieskovan S, Comin-Anduix B, Wu A, Charych DH, Ribas A. Enhanced Expansion and Tumor Targeting of Adoptively Transferred T Cells with NKTR-214. Session PO.CL06.03 - Adoptive Cell Therapy 3. American Association for Cancer Research Annual Meeting 2018.

IsoPlexis Uses Single-Cell Platform to Assess T Cell Activity in CAR-T Cancer Therapy. The work was part of a larger study looking at the effectiveness of ACT in combination with the cytokine agonist NKTR-214. The study, led by Antoni Ribas, director of the tumor immunology program at UCLA's Jonsson Comprehensive Cancer Center, found that the ACT-NKTR-214 combination improved the induction of cytotoxic T cells and increased their polyfunctionality, indicating that addition of NKTR-214 could boost the performance of ACT. NKTR-214 is produced by San Francisco-based biopharma company Nektar Therapeutics, which also participated in the study. "The finding in a preclinical model that the IsoPlexis assay can detect a remarkable increase in polyfunctionality in tumor-infiltrating lymphocytes recovered from tumors of mice treated with NKTR-214 compared to IL-2 is the most conclusive data we have obtained in this model system," said Ribas.

Contact us to find out more about how IsoPlexis can help your organization.